The protein cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential negative regulator of immune responses, and its loss causes fatal autoimmunity in mice. We studied a large family in which five individuals presented with a complex, autosomal dominant immune dysregulation syndrome characterized by hypogammaglobulinemia, recurrent infections and multiple autoimmune clinical features. We identified a heterozygous nonsense mutation in exon 1 of CTLA4. Screening of 71 unrelated patients with comparable clinical phenotypes identified five additional families (nine individuals) with previously undescribed splice site and missense mutations in CTLA4. Clinical penetrance was incomplete (eight adults of a total of 19 genetically proven CTLA4 mutation carriers were considered unaffected). However, CTLA-4 protein expression was decreased in regulatory T cells (T reg cells) in both patients and carriers with CTLA4 mutations. Whereas T reg cells were generally present at elevated numbers in these individuals, their suppressive function, CTLA-4 ligand binding and transendocytosis of CD80 were impaired. Mutations in CTLA4 were also associated with decreased circulating B cell numbers. Taken together, mutations in CTLA4 resulting in CTLA-4 haploinsufficiency or impaired ligand binding result in disrupted T and B cell homeostasis and a complex immune dysregulation syndrome.
The protein cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential negative regulator of immune responses, and its loss causes fatal autoimmunity in mice. We studied a large family in which five individuals presented with a complex, autosomal dominant immune dysregulation syndrome characterized by hypogammaglobulinemia, recurrent infections and multiple autoimmune clinical features. We identified a heterozygous nonsense mutation in exon 1 of CTLA4. Screening of 71 unrelated patients with comparable clinical phenotypes identified five additional families (nine individuals) with previously undescribed splice site and missense mutations in CTLA4. Clinical penetrance was incomplete (eight adults of a total of 19 genetically proven CTLA4 mutation carriers were considered unaffected). However, CTLA-4 protein expression was decreased in regulatory T cells (T reg cells) in both patients and carriers with CTLA4 mutations. Whereas T reg cells were generally present at elevated numbers in these individuals, their suppressive function, CTLA-4 ligand binding and transendocytosis of CD80 were impaired. Mutations in CTLA4 were also associated with decreased circulating B cell numbers. Taken together, mutations in CTLA4 resulting in CTLA-4 haploinsufficiency or impaired ligand binding result in disrupted T and B cell homeostasis and a complex immune dysregulation syndrome.
Adaptive immune responses must balance the response against foreign antigens with the need to avoid damage to host tissue. Inefficient activation of the immune response results in pathology due to infections, whereas overactivation may drive an autoimmune response. It might be expected that distinct genetic mutations underlie these apparently opposite outcomes, yet, paradoxically, it is well recognized that autoimmunity and immunodeficiency can manifest concurrently in the same individuals 1 .
Common variable immunodeficiency (CVID) is the most frequent primary immunodeficiency in humans characterized by low immunoglobulin levels, recurrent upper respiratory tract infections and impaired vaccination responses 2, 3 . In many patients, CVID presents as an immune dysregulation syndrome with autoimmunity, granulomatous disease, enteropathy, and malignancy 4 . The majority of familial CVID cases present an autosomal dominant pattern of inheritance, yet disease penetrance may appear incomplete owing to the late onset of symptoms 5 . Dominant mutations causing CVID have been found in NFKB2 (ref. 6) , and some patients with activating PIK3CD mutations present with a CVID-like phenotype 7 . Still, most autosomal dominant mutations causing CVID or increasing the disease risk remain to be identified.
The mammalian immune system contains self-reactive T cells, which are controlled by forkhead box P3-positive (FOXP3 + ) T reg cells 8, 9 . Accordingly, T reg deficiency caused by mutations in FOXP3 leads to an aggressive autoimmune syndrome termed IPEX (immune dysregulation polyendocrinopathy X-linked) 10 . In mice, deficiency of CTLA-4 results in a lethal autoimmune phe-
RESULTS

Identification of heterozygous mutations in CTLA4
We carried out whole-exome sequencing and genetic linkage analysis in 14 members of a large family with 39 individuals (family A, Fig. 1a and Supplementary Note 1). Five family members were diagnosed with CVID or selective IgA deficiency and presented with recurrent respiratory tract infections, hypogammaglobulinemia, autoimmune cytopenia, autoimmune enteropathy and granulomatous infiltrative lung disease. Because we could not identify any perfectly segregating novel mutations in these individuals, we performed an affected-only analysis to allow for reduced penetrance of the causative mutation. We identified 27 novel heterozygous mutations in 19 genes, which had not been listed in the dbSNP database (Supplementary Fig. 1 ), among them a nonsense mutation at position c.105 (C35*) in the first exon of CTLA4 that segregated with disease. This mutation also occurred in six members of family A who were so far considered healthy (I.2, II.2, II.3, II.10, III.5 and III.6) (Fig. 1a) .
Screening of 71 unrelated patients with CVID and enteropathy or autoimmunity revealed five additional index patients with novel CTLA4 mutations. Working up the family histories revealed four more patients and two CTLA4 mutation carriers, yielding a total of six families (A-F) containing 14 patients (11 of them with a genetically proven heterozygous notype 11, 12 with marked similarities to FOXP3 deficiency 8, 13, 14 . CTLA-4 is an essential effector component of T reg cells that is required for their suppressive function in certain settings [15] [16] [17] [18] [19] . The mechanism by which CTLA-4 functions is still debated [20] [21] [22] ; however, studies in chimeric mice containing a mixture of wildtype and Ctla4 -/-cells suggest that in vivo CTLA-4 primarily acts in a T cell-extrinsic manner 23, 24 . In keeping with a T cell-extrinsic mechanism of action, it has been recently shown that CTLA-4 can function by removing its ligands (CD80 and CD86) from antigenpresenting cells (APCs) via transendocytosis 25 . These CTLA-4 ligands are shared with the stimulatory receptor CD28 (ref. 26) , whose engagement drives T cell activation, cytokine production and memory T cell differentiation 27, 28 . Depletion of the co-stimulatory ligands CD80 and CD86 by CTLA-4 reduces APC-mediated activation of conventional T cells via CD28, resulting in dominant suppression of T cell activation 21 . Thus, CTLA-4 and CD28 are linked to the control of both regulatory T cell suppression and effector T cell responses and sit at a nexus between autoimmunity and immunodeficiency. Following a hypothesis-free screening approach by nextgeneration sequencing, we identified CTLA4 mutations in humans resulting in impaired CTLA-4 function and a complex immune dysregulation syndrome. confirmed extensive CD4 + T cell infiltration in a number of organs including the intestines (Fig. 2a,b) , lungs ( Fig. 2c,d ), bone marrow ( Fig. 2f) , central nervous system (Fig. 2g,h ) and kidneys (Supplementary Note 2). We also found lymphadenopathy ( Fig. 2e) and hepatosplenomegaly in these individuals (Supplementary Note 2).
Activated T cells and reduced B cells in peripheral blood
Where sufficient blood samples were available, we carried out detailed immunological investigations in families A-D. Consistent with the observed lymphoproliferation and lymphocytic tissue infiltration, analysis of peripheral blood revealed evidence of increased T cell activation in CTLA4 +/-carriers and affected individuals, as assessed by reduced levels of CD4 + CD45RA + naive T cells (Fig. 3a) . Although the affected individuals generally had lymphopenia in the periphery (Supplementary Table 2 ), the ratio of CD4 + to CD8 + T cells was in the normal range (Supplementary Fig. 3a ). All symptomatic patients with CTLA4 mutations except B.II.1 had reduced levels of at CTLA4 mutation; for three patients (A.II.8, B.II.2 and B.III.2) no genomic DNA was available as they had died before this study) and eight carriers (Fig. 1a) . Seven of the 14 patients fulfilled the diagnostic criteria of CVID. A splice-site mutation (family B) and a mutation in the start codon (family F), comparable to the nonsense mutation in family A, were predicted to result in haploinsufficiency due to a lack of CTLA-4 expression from one allele (Fig. 1b) . Three distinct missense mutations (families C-E) affected conserved amino acids in the extracellular domain (Fig. 1b) and were predicted to interfere with ligand binding or CTLA-4 stability (Supplementary Fig. 2 ). Lymphocytic organ infiltration and lymphadenopathy Ctla4 -/-mice die from CD4 + T cell-dependent organ infiltration 11, 12, 29 . indicate that two functional CTLA4 alleles appear necessary to drive the high levels of protein required in activated T reg cells.
Ligand binding and capture is impaired by CTLA4 mutations
To investigate CTLA-4 function, we tested the ability of T reg cells to perform transendocytosis 25 (see Supplementary Fig. 6 for assay design). We cocultured stimulated CD4 + FOXP3 + T cells with CD80-GFP-expressing Chinese hamster ovary (CHO) cells and analyzed their ability to capture ligand by flow cytometry (Fig. 4a) . T reg cells from healthy CTLA4 +/+ individuals transendocytosed efficiently with 10-25% becoming positive for CD80-GFP; this percentage was reduced to only 2-3% in individuals bearing CTLA4 mutations, indicating a deficit in ligand capture. Transendocytosis of CD80 was inhibited when a blocking CTLA-4-specific antibody was added to cell cultures, confirming that the ligand capture was CTLA-4 dependent (Fig. 4a) .
To study the impact of CTLA4 point mutations in the absence of coexpressed wild-type protein, we cloned the CTLA4 mutants identified in our patients, expressed these in CHO cells and used these cells for soluble CD80 ligand uptake assays (Fig. 4b) . We assessed protein expression by permeabilizing the cells and using an antibody that recognizes an epitope in the cytoplasmic domain of CTLA-4. This avoided antibody staining least one immunoglobulin isotype (Supplementary Table 2 ); seven out of ten patients had low proportions of CD19 + B cells (Fig. 3a) and low numbers of switched (IgM -CD27 + ) memory B cells (Fig. 3a) . Additional characterization of the lymphocyte compartment is shown in Supplementary Figure 3a and Supplementary Table 2. In five out of six patients who were monitored over at least 2 years, we observed a progressive loss of CD19 + B cells over time ( Supplementary Fig. 4) . In vitro re-stimulation of T cells from affected individuals did not suggest a bias toward T helper type 1, 2 or 17 differentiation (Fig. 3b) . As some affected individuals showed T cell infiltrates into multiple organs, we were interested in whether their T cells had a polyclonal distribution of T cell receptors (TCRs). We observed that A.II.5 had an oligoclonally expressed T cell receptor b, g and d repertoire in the peripheral blood, whereas A.III.3 had a normal distribution (Supplementary Fig. 3b) . The oligoclonal T cell repertoire of A.II.5 was confirmed by TCR spectratyping (Supplementary Fig. 3c ).
CTLA-4 expression is reduced in T reg cells
Given the role of CTLA-4 in T reg cell function 19 , we analyzed the T reg cell compartment in symptomatic individuals or healthy carriers bearing CTLA4 mutations. The frequency of FOXP3 + T reg cells within the CD4 + T cell compartment was higher in individuals with a heterozygous CTLA4 mutation compared to healthy CTLA4 +/+ controls (Fig. 3c) . Consistent with this, both homozygous 30 and heterozygous loss of Ctla4 in mice (Supplementary Fig. 5 ) are associated with an increased frequency of T reg cells. To investigate the impact of the mutations on CTLA-4 protein expression, we carried out intracellular staining for CTLA-4. CTLA-4 expression was reduced in FOXP3 + T cells from all individuals with CTLA4 mutations compared with healthy CTLA4 +/+ control cells (Fig. 3d) , a deficit that was more pronounced following T cell activation. Thus, in healthy control subjects, activated T reg cells expressed levels of CTLA-4 in excess of those in the FOXP3 -conventional T cell population. In contrast, in individuals with CTLA4 mutations, the expression of CTLA-4 in activated T reg cells was similar to the expression in activated conventional T cells. Taken together, these data suppressed CD4 + T cell proliferation, and this was reversed by a CTLA-4-specific blocking antibody, indicating that the suppressive function of the T reg cells in this assay is CTLA-4 dependent (Fig. 4c) . T reg cells from individuals with heterozygous CTLA4 mutations were unable to suppress CD4 + T cell proliferation as compared to healthy CTLA4 +/+ controls (Fig. 4c) . These data reveal a defect in the CTLA-4-dependent suppressive activity of T reg cells from individuals carrying heterozygous CTLA4 mutations.
DISCUSSION
CD28 co-stimulation is required for T cell effector function and generation of T memory cells, and it also influences B cell class switching and T reg cell homeostasis 32 . These processes are negatively regulated by CTLA-4. Interfering with the CD28-CTLA-4 pathway can therefore have both immune-stimulatory and immune-inhibitory effects [33] [34] [35] . Here, we report the phenotype of patients with previously undescribed heterozygous mutations in CTLA4 providing clear evidence of its importance in immune homeostasis and T reg cell suppressive function. In families A, B and F, the CTLA4 mutations most likely ablate CTLA-4 protein expression, rendering individuals haploinsufficient for CTLA-4. From these families, we learn that the gene dosage of CTLA4 being compromised by the mutations in the extracellular domain (Fig. 4b) . We detected full-length CTLA4 protein in cells transfected with the CTLA4 mutants R70W (family C) and T124P (family D ; Fig. 4b ). In contrast, we found no protein expression in cells transfected with the C35* (family A) mutant, ruling out the use of an alternative start codon at Met38 immediately downstream of the premature stop codon. Cells transfected with either the T124P or the R70W mutant were impaired in their ability to take up soluble CD80-immunoglobulin fusion protein (CD80-Ig) (Fig. 4b) . Thus, although these mutations are not within the known MYPPPY ligand-binding motif of CTLA-4 (ref. 31) (Supplementary Fig. 2) , they appear to impair ligand binding and uptake.
CTLA4 mutations impair T reg cell suppression
We tested the impact of CTLA4 heterozygosity on regulatory T cell function in vitro using T cells and dendritic cells from healthy donors as targets for suppression. Under control conditions, naive CD4 + cells proliferated in response to CD3-specific antibodies and cocultured dendritic cells (Fig. 4c) . Proliferation was CD80 and CD86 liganddependent, as it was inhibited by the addition of CTLA-4-Ig (abatacept ;  Fig. 4c) . Addition of control T reg cells from healthy donors efficiently Relative CD80-GFP uptake note their use of whole peripheral blood mononuclear cells (PBMCs) and stimulation with CD3-specific and CD28-specific antibodies 43 . Given the enrichment of memory T cells in the patient samples, along with the presence of T reg cells in these assays, it is unclear whether the hyperproliferative T cell phenotype reported is necessarily due to loss of CTLA-4 function in conventional T cells. The relative role of CTLA-4 in T reg cells versus conventional T cells remains unclear, and additional work is needed to establish whether there is T cell-intrinsic hyperproliferation in patients bearing CTLA4 mutations. In addition, whereas Kuehn et al. 43 report CTLA-4 expression on B cells, we were unable to detect CTLA-4 expression on B cells in the conditions we tested (Supplementary Fig. 7 ). Despite these differences in immunological detail, together our studies make a compelling argument that quantitative deficiencies in CTLA-4 protein expression predispose individuals to both autoimmunity and immunodeficiency.
Alterations in immune homeostasis are a feature of primary immunodeficiency, and organs with surfaces exposed to microbes, including the intestine, lungs and skin, seem to be particularly vulnerable to infections. The discovery of heterozygous loss-of-function mutations in CTLA4 suggests that the CD28 and CTLA-4 pathway may be therapeutically targeted in selected subsets of patients with inflammatory bowel disease, enteropathy and wasting disease, granulomatous lung disease and autoimmune cytopenias. Soluble CTLA-4 fusion proteins (abatacept and belatacept), which bind to CD80 and CD86 and inhibit immune activation, have proven beneficial for the treatment of autoimmune disease and prevention of organ rejection 35, 44, 45 . Whether they could be beneficial in the context of CTLA-4 deficiency warrants investigation.
METHODS
Methods and any associated references are available in the online version of the paper. is important, especially for the function of regulatory T cells. In families C-E, the mutations affect the ligand binding of CTLA-4, impairing the interaction of CTLA-4 with CD80 and CD86. As CTLA-4 forms homodimers and clusters with its ligands, these mutants may exert a dominant-negative effect.
Of 19 individuals with a proven heterozygous mutation in CTLA4, 12 presented with severe clinical manifestations. The availability of samples from currently healthy family members carrying the CTLA4 mutation provided an opportunity to examine the consequences of this mutation in a setting uncoupled from illness or treatment. Notably, those individuals tested so far also exhibited a similar reduction in CTLA-4 expression, CTLA-4-dependent transendocytosis and T reg cell suppressive function. This suggests that additional modifiers, including genetic, epigenetic or environmental factors, may exist that influence the clinical outcome of CTLA-4 deficiency 36 . As the age of disease onset for clinical symptoms associated with CTLA-4 deficiency ranges in our patient cohort from 7 to 40 years, currently healthy, young mutation carriers may develop disease later. Indeed, autoimmune features (for example, psoriasis, type 1 diabetes and prolonged episodes of diarrhea) are evident in carriers previously classified as healthy (Supplementary Table 1 ). The breadth of autoimmune targets in patients and carriers is consistent with the range of autoimmunity reported in the setting of Foxp3 deficiency 37 .
One notable finding is that patients with defects in CTLA-4 expression and function present with hypogammaglobulinemia in immunodeficiency clinics. Given that CTLA-4 inhibits the CD28 pathway, which plays a role in T cell help for B cell responses, deficiency in CTLA-4 might be expected to enhance CD28 function and promote humoral immunity. One possible explanation is that hyperactivation of T cells may result in infiltration and disruption of the bone marrow niche, impairing B cell development. This is consistent with the disruptions in B cell lymphopoiesis in T reg cell-deficient mice 38 . Alternatively, increased CD28-dependent follicular helper T cell differentiation 39 could result in chronic stimulation of B cells, leading to exhaustion. There may also be parallels with the phosphoinositide 3-kinase d-activating mutations 40, 41 that cause defects in B cell class switching despite hyperactivation of T cell responses. As CD28 is a major phosphoinositide 3-kinase activator in T cells 42 , this link warrants future investigation.
Kuehn et al. 43 recently reported a group of patients with heterozygous CTLA4 mutations. The clinical phenotype of their patients bears considerable similarity to those reported herein, and they also report incomplete penetrance of the disease phenotype, suggesting that CTLA-4 deficiency leads to a broad, yet well-defined, clinical syndrome. Our patient cohort contains different mutations from those of Kuehn et al. 43 , suggesting there may be a spectrum of genetic alterations leading to defective CTLA-4 function. We have identified several point mutations in the ectodomain of the expressed CTLA-4 protein. Although we show in cellular assays that ligand binding to these mutants is impaired, it remains to be formally determined whether this impairment is solely due to changes in CTLA-4 affinity for its ligands or whether CTLA-4 structural stability is affected.
The binding of CTLA-4 to its ligands is closely coupled to its function as a competitor for CD28 co-stimulation. Accordingly, T reg cell function, which requires the ability of CTLA-4 to bind to and remove its ligands from APCs, is impaired in individuals bearing CTLA4 mutations. Given the key role of CTLA-4-ligand interactions, it is important in our view to study CTLA-4 in the context of CD80-or CD86-dependent T cell activation to probe its function. In this respect, although the defects in T reg cell suppressive function in individuals with CTLA4 mutations are consistent with those in Kuehn et al. 43 , we did not observe any obvious alterations in conventional T cell proliferation (data not shown). There are numerous possible explanations for such differences; however, we Human T reg suppression assays. To study CTLA-4-dependent T reg suppression, conditions were established where stimulation of responder T cells (by DCs plus anti-CD3) was shown to be sensitive to blockade by abatacept (CTLA-4-Ig). This ensures that the response is sensitive to the presence of CD80 and CD86 ligands on the APC and thereby sensitive to ligand removal by CTLA-4-expressing T reg cells. In our experience, T cell responses that are not abatacept sensitive such as those stimulated using antibody-coated beads cannot be suppressed in a CTLA-4-dependent manner by T reg cells. To perform such assays, freshly isolated resting CD4 + naïve T cells were washed with PBS and incubated with CellTrace Violet according to the manufacturer's instructions (Molecular Probes). The reaction was quenched with media containing serum followed by PBS wash, and cells were suspended at 1.8 × 10 6 cells/ml before use as responder T cells. T cell proliferation assays were performed in 250 µl RPMI 1640 culture media. Responder T cells (0.9 × 10 5 ) were stimulated with 0.5 µg/ml CD3-specific antibody (OKT3-ATCC). To provide co-stimulation, monocyte-derived DCs expressing CD80 and CD86 were used. To generate these, monocytes (2 × 10 6 cells/ml) were cultured in RPMI 1640 medium containing 10% FCS and antibiotics with GM-CSF (PeproTech, 800 U/ml) and IL-4 (PeproTech, 500 U/ml) for 5-7 d. DCs were present at a ratio of 1:10, DC to T cell. Cells were cultured for 5 d in the presence or absence of 10 µg/ml CTLA-4-Ig (abatacept) or anti-CTLA-4 (20 µg/ml). To measure T reg suppression, unlabeled negatively selected CD4 + CD25 + T reg (2 T reg cells to 1 DC) were added. Division of responder T cells was measured by the dilution of violet dye using flow cytometry. Live proliferating T cell counts were performed using counting beads (Dako) and analyzed using FlowJo software.
Statistical analyses. Unless otherwise indicated, statistical analysis was performed using GraphPad Prism version 6, and P values were calculated by twotailed unpaired Student's t-test for the means with a 95% confidence interval. In Supplementary Figure 5 , a two-sided Mann-Whitney U test was performed.
